Introduction/Background Pelvic exenteration is a major surgical procedure for advanced or recurrent gynaecological cancer. It is a potentially curative treatment but it could also be performed with palliative intent. Locally advanced vulvar cancer is rare and extremely challenging to manage. We aim to report our experience with pelvic exenteration for locally advanced vulvar cancer in our centre.

Methodology All patients undergoing pelvic exenteration between December 2014 and April 2019 at the Swansea Gynaecological Oncology Centre were identified through our surgical database. Patient characteristics, the indications for the procedure, pathology results and outcomes were retrospectively analysed. We used frequencies and percentages to describe the sample. Mean values were calculated where appropriate. Statistical analyses were performed with IBM SPSS 25.0 (SPSS Inc, Chicago, IL, USA).

Results 6 women were identified who had pelvic exenteration for locally advanced vulvar cancer during the study period. All were squamous cell carcinoma. The mean age of the women was 54.2 years (42–64 years). 5 women underwent posterior pelvic exenteration while 1 women underwent total pelvic exenteration. 3 patients required VRAM flap. 2 women died during the study period but they had pelvic exenteration with palliative intent and both had positive margins on histology, with an average survival of 8.5 months. The remaining 4 women had negative margins on histology and are still alive despite 3 of them having positive lymph nodes. 4 women had a form of radiotherapy or chemotherapy or both.

Conclusion Pelvic exenteration is a major procedure with high morbidity but it is a reasonable treatment option for women with locally advanced vulvar cancer for both curative and palliative intent. We continue to closely follow up all our patients.

Disclosure Nothing to disclose